SCHEMBL5215416

SCHEMBL5215416

O=Cc1ccc(OCc2ccc(F)cc2F)c(OCc2ccc(F)cc2F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
MEN1 O00255 1/20 0.65
POLB P06746 1/20 0.65
HPGD P15428 1/20 0.65
KMT2A Q03164 1/20 0.65
GSK3B P49841 2/20 0.50
BACE1 P56817 2/20 0.50
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
IDO1 P14902 2/20 0.46
AGXT P21549 2/20 0.46
TACR2 P21452 1/20 0.46
FDPS P14324 1/20 0.45
MAOB P27338 1/20 0.45
PKM P14618 1/20 0.44
CCR5 P51681 1/20 0.44
MAPK14 Q16539 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14078205 0.92 ALDH1A1 (0.74) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL5217217 0.91 ALDH1A1 (0.56) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL2930304 0.84 ALDH1A1 (0.57) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL2927947 0.83 ALDH1A1 (0.56) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL5628276 0.82 MEN1 (0.53) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL30628479 0.80 TACR2 (0.63) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL5218194 0.80 TACR2 (0.63) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL5504480 0.79 ALDH1A1 (0.64) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL12769016 0.79 ALDH1A1 (0.57) ALDH1A1MEN1POLBHPGDKMT2A
SCHEMBL5628701 0.78 ALDH1A1 (0.54) ALDH1A1MEN1POLBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313471-B1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS UCB SA (BE) 2007-04-11 EP disclosed
US-7105554-B2 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2006-09-12 US disclosed
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-01-08 US disclosed
EP-1313471-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002017915-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents SLC5A2, OXSR1, SLC5A1 ALDH1A1 2757/4885MEN1 1143/4885POLB 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.